Article

From Categorical to Continuous: A Symbiotic Human-AI Approach to HER2 Scoring in the Antibody-Drug Conjugates Era

2025-12-18

Abstract excerpt

<title>Abstract</title> <p>The advent of antibody-drug conjugates (ADCs) has fundamentally transformed HER2 assessment in breast cancer, shifting therapeutic focus from gene amplification to protein expression levels. This paradigm exposes critical limitations in traditional categorical scoring: inability to preserve expression gradients, poor interobserver agreement at clinically relevant boundaries, and systema...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2cd5a205-9177-5c99-8538-cdb0597fa6d4
DOI: 10.21203/rs.3.rs-8372972/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

From Categorical to Continuous: A Symbiotic Human-AI Approach to HER2 Scoring in the Antibody-Drug Conjugates EraDOI 10.21203/rs.3.rs-8372972/v1Read

Triple-negative breast cancer: a threshold-defined diagnostic category within a biological continuum.Semantic proximity Read

Hierarchically supervised computational pathology stratifies HER2 categories and ERBB2 amplification risk from routine H&E slides in breast cancerSemantic proximity Read

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast CancerSemantic proximity Read

Impact of a machine learning-powered algorithm on pathologist HER2 IHC scoring in breast cancerSemantic proximity Read

ADC Target Profiling in NSCLC: Generalizable AI Separates TROP-2 and cMET Phenotypes.Semantic proximity Read

Validation and Prospective Testing of a High Sensitivity, Quantitative Analytic Assay for HER2 on Histopathology SlidesSemantic proximity Read

The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 statusSemantic proximity Read

Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes.Semantic proximity Read

Low and Ultra-low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic SubtypesSemantic proximity Read

Artificial Intelligence Model’s assessment of intra-sample heterogeneity of HER2 IHC in breast cancer is related to interobserver and intraobserver agreement among pathologistsSemantic proximity Read

Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatmentSemantic proximity Read

Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond.Semantic proximity Read